Bioresorbable Coronary Stents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Brand (Magmaris, Magnitude, MeRes-100, DESolve, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region & Competition, 2020-2030F

Market Overview

Global Bioresorbable Coronary Stents Market was valued at USD 550.09 Million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 10.25% through 2030. The field of cardiology has witnessed remarkable advancements in recent years, leading to better patient outcomes and improved quality of life for individuals with coronary artery disease (CAD). Among these advancements, bioresorbable coronary stents have emerged as a promising innovation. These stents represent a significant shift in the treatment of CAD, offering a solution that gradually dissolves within the body after its purpose is served.

Coronary artery disease is a prevalent cardiovascular condition characterized by the buildup of plaque inside the coronary arteries, which can restrict blood flow to the heart muscle. Left untreated, CAD can lead to chest pain (angina), heart attacks, and even heart failure. Traditionally, CAD has been treated using metal stents, which are implanted to keep the arteries open. However, these permanent metallic implants have their limitations. Bioresorbable coronary stents, also known as bioresorbable vascular scaffolds (BVS), are a game-changer in the field of interventional cardiology. Unlike their metallic counterparts, bioresorbable stents are designed to be gradually absorbed by the body over time. They are typically made from materials such as polylactic acid, polyglycolic acid, or a combination of both. The stent provides structural support to the artery during the initial stages of healing and vessel remodeling, and then naturally dissolves, leaving behind a healed artery.

The bioresorbable coronary stents market has witnessed significant growth over the past decade, driven by several factors. Clinical studies have demonstrated the safety and efficacy of bioresorbable stents, showing comparable outcomes to traditional metallic stents. Patients treated with bioresorbable stents experience reduced long-term complications associated with permanent metallic stents, such as in-stent restenosis and late stent thrombosis. Ongoing research and development efforts have led to the refinement of bioresorbable stent designs, making them more suitable for a wider range of patients. Cardiologists and interventional radiologists are increasingly embracing bioresorbable stents due to their patient-centric benefits and the potential for improved clinical outcomes.

Key Market Drivers

Rising Prevalence of Cardiovascular Diseases (CVDs)

The increasing global burden of cardiovascular diseases (CVDs) is one of the most significant drivers fueling the growth of the Global Bioresorbable Coronary Stents Market. Cardiovascular diseases (CVDs) remain the leading global cause of mortality, accounting for 17.9 million deaths in 2019, which represents 32% of total global fatalities. Notably, 85% of these deaths resulted from heart attacks and strokes. Furthermore, over 75% of CVD-related deaths occur in low- and middle-income countries, highlighting a critical disparity in healthcare access and cardiac treatment infrastructure. As the number of patients diagnosed with coronary artery disease (CAD) continues to surge, the demand for innovative and effective treatment solutions such as bioresorbable coronary stents (BRS) is rising.  Coronary artery disease, a leading form of CVD, results from the narrowing or blockage of coronary arteries due to atherosclerosis (buildup of plaque). In 2022, the global prevalence of coronary artery disease (CAD) reached 315 million cases, with a 95% uncertainty range of 273 million to 362 million. The age-standardized prevalence rate was recorded at 3,605 cases per 100,000 individuals, with a range of 2,892 to 4,454 per 100,000, underscoring the widespread burden of CAD across diverse populations. The aging global population is a key contributor, as older individuals are more susceptible to CAD. Age remains the most significant nonmodifiable risk factor for coronary artery disease (CAD) and other cardiovascular conditions in older adults. According to the American Heart Association (AHA) 2019 update, 31% of men and 25.4% of women aged 80 and above are diagnosed with CAD, highlighting the increased disease prevalence in aging populations. Rising cases of hypertension, diabetes, and high cholesterol further accelerate the need for effective cardiac interventions. The increasing prevalence of obesity and sedentary lifestyles has exacerbated cardiovascular risks, particularly in developed and developing economies alike. With more patients requiring coronary interventions, bioresorbable stents are emerging as a superior alternative to traditional metallic stents, driving their market growth.

Governments and healthcare organizations worldwide are promoting early diagnosis and preventive care to reduce CVD-related mortality rates. Routine health check-ups and advanced imaging technologies (e.g., CT angiography, stress tests) are leading to the earlier detection of CAD. Patients diagnosed in the early to mid-stages of coronary artery blockage are increasingly being treated with percutaneous coronary intervention (PCI) instead of open-heart surgery. As PCI remains the preferred treatment approach, the adoption of bioresorbable stents is rising due to their ability to provide temporary arterial support while eventually dissolving, restoring normal vascular function. This proactive approach to cardiac care is boosting demand for advanced stent technologies, including bioresorbable coronary stents. Traditional metallic drug-eluting stents (DES), while effective, present long-term complications such as: Late stent thrombosis (blood clot formation around the stent). Chronic inflammation due to the permanent presence of a foreign object. Restricted vascular motion after stent placement. In contrast, bioresorbable coronary stents offer a temporary scaffold that dissolves over time, reducing long-term risks while allowing the artery to regain its natural flexibility. As more cardiologists and healthcare providers recognize these clinical advantages, they are increasingly recommending bioresorbable stents for patients, particularly younger individuals and those at high risk of restenosis.

Rising Patient Preference for Minimally Invasive Procedures

The preference for minimally invasive procedures has been steadily growing among patients, and this trend is a significant driver behind the increasing adoption of bioresorbable coronary stents. One of the most compelling reasons patients opt for minimally invasive procedures is the quicker recovery time. Compared to traditional open-heart surgeries, procedures involving bioresorbable stents are less invasive and often require shorter hospital stays. Minimally invasive procedures typically cause less pain and discomfort compared to their invasive counterparts. Smaller incisions and less tissue trauma contribute to a more comfortable post-operative experience. Minimally invasive procedures carry a lower risk of complications, such as infection and bleeding, which can be significant concerns with traditional surgeries. Patients can return to their regular activities sooner after minimally invasive procedures, leading to an overall improvement in their quality of life.

The patient preference for minimally invasive procedures aligns perfectly with the unique benefits of bioresorbable coronary stents. As more patients become aware of these advantages, there has been a significant increase in demand for BRS, thereby driving market growth. Patients are increasingly requesting bioresorbable stents, and healthcare providers are responding to this demand by incorporating these devices into their treatment options. Medical device manufacturers are investing in research and development to improve bioresorbable stent designs and materials, further enhancing their safety and effectiveness. Regulatory bodies are actively working to establish guidelines and standards for bioresorbable stents, ensuring their safety and efficacy, which in turn bolsters patient confidence.

Expanding Healthcare Infrastructure & Rising Medical Expenditure

The Global Bioresorbable Coronary Stents Market is experiencing significant growth due to the rapid expansion of healthcare infrastructure and increasing medical expenditure across both developed and developing regions. As governments and private entities continue to invest heavily in healthcare systems, access to advanced cardiac treatments—including bioresorbable coronary stents (BRS)—is expanding.  Many countries are prioritizing healthcare improvements through public and private sector investments to enhance medical infrastructure, which directly contributes to the adoption of advanced cardiovascular treatments like bioresorbable stents. The surge in government expenditures due to pandemic-related healthcare responses drove global health spending to approximately USD9 trillion in 2020, representing nearly 11% of the global GDP. Notably, public sector funding accounted for 63% of this total, reflecting a substantial shift toward state-backed healthcare investments. Governments worldwide are allocating higher healthcare budgets to improve hospital infrastructure, expand specialized cardiac units, and ensure access to cutting-edge medical technologies. Countries with universal healthcare programs (such as Canada, the UK, and Germany) are increasingly subsidizing PCI (percutaneous coronary intervention) procedures, making bioresorbable stents more accessible to patients. Emerging economies (such as India, China, and Brazil) are heavily investing in public health initiatives to combat the rising burden of cardiovascular diseases, leading to increased adoption of advanced treatment solutions. Private healthcare providers are expanding their networks of hospitals and specialty clinics, increasing the availability of state-of-the-art cardiac interventions.

Medical tourism hubs such as Thailand, Singapore, and the UAE are investing in high-end medical technologies, including bioresorbable stents, to attract international patients. These financial investments are accelerating the adoption of bioresorbable stents, especially in regions where access to advanced cardiac care was previously limited. According to the World Health Organization (WHO), global healthcare spending is rising significantly, Aging populations requiring more frequent cardiac treatments. Growing middle-class populations in developing countries with higher disposable incomes for premium healthcare services. Increased insurance coverage for advanced medical procedures. As spending on cardiac care and minimally invasive procedures rises, hospitals and healthcare facilities are adopting bioresorbable coronary stents to meet growing demand. In many countries, insurance providers are expanding coverage for advanced cardiac procedures, including bioresorbable stents, making them more financially accessible to patients. In regions where out-of-pocket medical expenses are high (such as the U.S. and parts of Asia), private insurers are offering competitive reimbursement plans, encouraging more patients to opt for cutting-edge stent technologies. Greater financial accessibility translates into higher adoption rates of bioresorbable stents, further fueling market expansion.

Download Free Sample Report

Key Market Challenges

Efficacy and Safety Concerns

One of the primary challenges in the bioresorbable coronary stents market is ensuring the safety and efficacy of these devices. Clinical trials have raised concerns about the rate of stent thrombosis, which is the formation of blood clots within or around the stent. This issue can lead to life-threatening complications and has prompted questions about the overall safety of bioresorbable stents compared to traditional metallic stents.

Lack of Long-term Data

Long-term data on the performance of bioresorbable coronary stents is limited. While they offer the advantage of being absorbed by the body over time, questions remain about their long-term durability and effectiveness in preventing restenosis (the re-narrowing of arteries). Physicians and patients are often more comfortable with proven metallic stents due to their extensive track record.

Manufacturing Complexity

The production of bioresorbable stents is more complex than that of traditional stents. Ensuring consistency in stent composition, strength, and resorption rates is challenging. Any variability in these factors can impact patient outcomes and lead to regulatory hurdles.

Key Market Trends

Technological Advancements

The field of medical technology has seen remarkable advancements in recent years, revolutionizing the way we diagnose and treat various health conditions. One such innovation that has gained significant attention is the development of bioresorbable coronary stents. These innovative medical devices are transforming the way we manage coronary artery disease, and their rapid adoption can be attributed to the continuous technological advancements in the medical industry.

The choice of materials is pivotal in the development of bioresorbable coronary stents. Continuous research into biocompatible and bioresorbable materials has led to the creation of stents that can maintain their mechanical integrity during the initial stages of implantation while subsequently degrading harmlessly. Advancements in material science have contributed significantly to the safety and efficacy of these stents. Cutting-edge manufacturing techniques have enhanced the precision and quality of bioresorbable stents. 3D printing and laser cutting technologies allow for the production of stents with intricate designs that optimize radial strength and conformability to the vessel wall. Many bioresorbable stents are designed with drug-eluting properties. The controlled release of drugs from these stents reduces the risk of restenosis and inflammation, further improving patient outcomes. Technological advancements have allowed for better drug-loading techniques and more efficient drug-release profiles. Advances in imaging technologies such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) have provided physicians with detailed, real-time visualization of stent placement and expansion. This enables precise deployment and ensures optimal stent positioning, ultimately improving patient outcomes. Continuous research and clinical trials have played a significant role in fine-tuning bioresorbable stent designs and assessing their long-term safety and efficacy. These studies provide valuable data that guide further technological developments in the field.

Segmental Insights

End User Insights

Based on end used, Hospitals & Clinics Based segment emerges as the fastest growing segment in the Global Bioresorbable Coronary Stents Market during the forecast period. Hospitals and clinics are equipped with highly trained medical professionals, including cardiologists and interventional radiologists, who are skilled in performing procedures involving bioresorbable coronary stents. These medical experts are crucial for diagnosing and treating coronary artery disease, which often requires stent implantation. Hospitals and clinics have access to advanced medical equipment and facilities necessary for performing stent implantation procedures. This includes state-of-the-art catheterization labs, operating rooms, and post-operative care units, ensuring safe and effective stent placement. Hospitals and clinics serve as primary points of care for patients with coronary artery disease. Patients often visit these facilities for diagnosis, treatment planning, and follow-up care. This ensures a steady and reliable stream of patients who may require bioresorbable coronary stents. Hospitals and clinics collaborate closely with medical device manufacturers to stay updated on the latest technological advancements and product offerings in the field of bioresorbable coronary stents. They often participate in clinical trials and research studies, helping to drive innovation in this market segment. Hospitals, in particular, are well-equipped to handle emergency cases of acute coronary syndrome, where immediate intervention with stents may be necessary to save a patient's life. The availability of 24/7 emergency services in hospitals makes them indispensable for the treatment of such cases.

Download Free Sample Report

Regional Insights

North America emerged as the largest market in the global Bioresorbable Coronary Stents market in 2024, holding the largest market share in terms of value. North America, particularly the United States, boasts a highly developed healthcare infrastructure with state-of-the-art medical facilities, advanced research centers, and a well-established regulatory framework. This infrastructure supports the development, clinical testing, and adoption of innovative medical devices like bioresorbable coronary stents. North American countries invest significantly in biomedical research and development (R&D). This has led to the development of cutting-edge technologies and medical devices, including bioresorbable coronary stents. Collaboration between academic institutions, medical device companies, and healthcare providers fosters innovation in this field. The United States Food and Drug Administration (FDA) has stringent regulatory standards for medical devices, including coronary stents. While this can pose challenges, it also ensures that only safe and effective products reach the market. Companies that can meet these rigorous standards gain a competitive edge and can tap into the large patient population for clinical trials. North America has a well-trained and experienced healthcare workforce, including interventional cardiologists who are familiar with the latest medical technologies. They are more likely to adopt and recommend bioresorbable coronary stents when they become available.

Recent Developments

• In July 2024, MicroPort Scientific Corporation (00853.HK) announced that its wholly-owned subsidiary, Shanghai MicroPort Medical (Group) Co., Ltd., has secured market approval from the National Medical Products Administration (NMPA) for Firesorb, the world’s first next-generation fully bioresorbable cardiac stent. This milestone reinforces MicroPort’s leadership in advancing cardiovascular medical technology.
• In April 2024, Abbott announced that the U.S. Food and Drug Administration (FDA) has granted approval for its everolimus-eluting bioresorbable scaffold, Esprit BTK, designed for patients with below-the-knee (BTK) infrapopliteal disease. This approval marks a significant advancement in treatment options for peripheral artery disease (PAD).
• In July 2023, Lifetech Scientific Corp.'s three-year, first-in-humans trial demonstrated the safety and effectiveness of their fully biodegradable iron-based absorbable coronary scaffold for treating non-complex coronary lesions that had not been previously addressed with an interventional device.

Key Market Players

• BIOTRONIK SE & Co. KG
• Meril Life Sciences Pvt. Ltd
• Elixir Medical Corporation.
• Reva Medical, LLC
• Terumo Corporation
• Lepu Medical Technology (Beijing)Co.,Ltd
• MicroPort Scientific Corporation
• LifeTech Scientific Corporation
• Boston Scientific Corporation
• Medtronic plc

Report Scope:

In this report, the Global Bioresorbable Coronary Stents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Bioresorbable Coronary Stents Market, By Brand:

o   Magmaris

o   Magnitude

o   MeRes-100

o   DESolve

o   Others

• Bioresorbable Coronary Stents Market, By End User:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Bioresorbable Coronary Stents Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioresorbable Coronary Stents Market.

Available Customizations:

Global Bioresorbable Coronary Stents market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Bioresorbable Coronary Stents Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com